Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06802172 · ClinicalTrials.gov registry record · NA

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

A NA study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06802172 is a NA study of Breast Cancer Stage II and Breast Cancer Stage III that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 100 participants, below the 177-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06802172, a NA study of Breast Cancer Stage II and Breast Cancer Stage III, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response and metabolic health in an understudied population. This clinical trial will enroll patients with rectal or breast cancer receiving neoadjuvant treatment at the Alaska Native Medical Center (ANMC), which is part of the Alaska Native Tribal Health Consortium (ANTHC). A promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-clinical and clinical studies, various forms of fasting have been shown to induce tumor regression and improve long-term survival. According to the differential stress sensitization theory, fasting is thought to sensitize tumor cells to the cytotoxic effects of chemotherapy and radiation, while protecting healthy cells by increasing stress resistance. While healthy cells slow their growth and become more stress resistant in response to fasting, cancer cells cannot survive in nutrient-deficient environments; although the underlying mechanisms are not fully understood. However, extended water-only fasting can be challenging for patients and poses undue health risks. Intermittent fasting, and specifically time-restricted eating (TRE), may offer a viable alternative. TRE involves eating within a shorter window (e.g., 8 hours) and fasting for the remainder of the day but involves no other dietary restrictions. Because of its simplicity, TRE may be more sustainable than other fasting regimens. TRE also improves several cardio-metabolic endpoints, including insulin sensitivity, which may also be beneficial during anticancer treatments.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Questionnaire Administration
  • BEHAVIORAL Time-restricted eating
  • BEHAVIORAL Health coaching

Study Locations (1)

Alaska

  • Alaska Native Medical Center (ANMC) - Anchorage

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-03-31
Est. Completion 2029-08-31
Phase NA

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT06802172

The ClinicalTrials.gov registry entry for NCT06802172 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (44% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT06802172 reports 1 study location spanning 1 distinct geographic area - top geographies include Alaska.

Frequently Asked Questions

What is clinical trial NCT06802172 about?

NCT06802172 is a clinical study titled "Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial". The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response and metabolic health in an understudied population. This clinical trial will enroll patients with rectal or breast cancer receiving neoadj...

What is the current status of trial NCT06802172?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-03-31. Estimated completion is 2029-08-31.

What conditions does trial NCT06802172 study?

This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I, Solid Tumor Cancer, Rectal Cancer Stage II.

What interventions are being tested in trial NCT06802172?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Time-restricted eating (BEHAVIORAL), Health coaching (BEHAVIORAL).

Who is sponsoring clinical trial NCT06802172?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06802172 being conducted?

This trial has 1 study location across Alaska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Stage II

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.